ArticleFrontiers in oncology2020
Incidence, Prognostic Factors and Survival for Hemangioblastoma of the Central Nervous System: Analysis Based on the Surveillance, Epidemiology, and End Results Database.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.The Lancet. Oncology · 2024Trial
- Article
- Belzutifan-induced tumor regression in sporadic hemangioblastoma: a case report and literature review.Journal of neuro-oncology · 2026Review
- Exploring the Illness Experience of Patients with Central Nervous System Hemangioblastomas in Von Hippel-Lindau Disease: A Qualitative Study.Healthcare (Basel, Switzerland) · 2026Article
- Sporadic solid hemangioblastoma of the cerebellar vermis: A case report.Surgical neurology international · 2026Article
- Intracranial hemangioblastomas in children: Clinical-radiological characteristics, microsurgical strategy, and long-term outcomes in a 10-year single-center cohort.Brain & spine · 2026Article
- Fatal hemangioblastoma: a case report and literature review.Frontiers in oncology · 2026Review
- Gross total resection is associated with improvement and prognosis even in von Hippel-Lindau disease-related hemangioblastomas: Nationwide registry in Japan.Neuro-oncology practice · 2025Article
- Article
- Machine learning-driven national analysis for predicting adverse outcomes in intramedullary spinal cord tumor surgery.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2025Article
- Racial and socioeconomic disparities in long term survival after surgery and radiation for spinal cord hemangioblastoma.Scientific reports · 2025Article
- Freiburg Neuropathology Case Conference: Gait Ataxia, Segmental Hypoesthesia, and Combined Incontinence in a 57-Years-Old Patient.Clinical neuroradiology · 2025Article
- Factors that predict progression of von Hippel-Lindau disease-related malignancy: a longitudinal cohort study.BMC cancer · 2025Article
- Dual manifestations: spinal and cerebellar hemangioblastomas indicative of von Hippel-Lindau syndrome.Radiology case reports · 2024Article
- Spinal cord hemangioblastomas in von Hippel-Lindau disease.Neuro-oncology advances · 2024Review
- Trigeminal nerve hemangioblastoma in the setting of undiagnosed von Hippel-Lindau disease: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Radiosurgically Treated Recurrent Cerebellar Hemangioblastoma: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Time course of tumorigenesis of a newly developed sporadic hemangioblastoma in an elderly patient: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Patients With Hemangioblastoma: Mood Disorders and Sleep Quality.Brain tumor research and treatment · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemangioblastomas are uncommon, benign neoplasms of the central nervous system (CNS). This study aims to evaluate the incidence, demographics, clinical characteristics, and prognosis of CNS hemangioblastomas using the data from the Surveillance, Epidemiology, and End Results (SEER) Program.
methodsUnivariate and multivariate analyses using the Cox proportional hazards model were employed to identify prognostic factors of overall survival. The Kaplan-Meier method was utilized to evaluate overall survival distribution by treatment modality. A nomogram was further built to predict survival at 3 and 5 years.
resultsThe overall incidence rate of CNS hemangioblastomas was 0.141 per 100,000 person-years. Through univariate analysis and multivariate analyses, age between 60 and 79 years (HR = 3.697,
conclusionIn conclusion, age, race, tumor location, number of tumors, and prior surgery are prognostic factors for survival. Surgery was the most common modality and was suggested as an effective and optimal treatment. The proposed nomogram can predict the prognosis of patients with CNS hemangioblastomas and help clinicians in making decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.